Stay updated with breaking news from Test Abnormalities. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Patients treated with the investigational combination of trifluridine/tipiracil in combination with bevacizumab in the pivotal Phase 3 SUNLIGHT trial achieved clinically meaningful improvement in
BOSTON, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today announced
Early, rapid, and sustained efficacy across wide range of patients with evidence of disease modificationLong-term preservation of native liver in PFIC, improvements in pruritus, bile acids, and... | November 7, 2022
– New data presented at the North American Society for Pediatric Gastroenterology, Hepatology & Nutrition meeting – Earlier treatment with Bylvay provided greater efficacy in... | October 13, 2022
Highly statistically significant improvement in pruritus primary endpoint (p=0.002)Significant reductions in key secondary endpoint of serum bile acid levels (p=0.001)Substantial improvements in multiple